Sign in or create an account to add this stock to your watchlist.
About MEI Pharma (NASDAQ:MEIP)
MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MEIP
CUSIPN/A
Phone858-369-7100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.27
Quick Ratio8.27
Price-To-Earnings
Trailing P/E Ratio49.43
Forward P/E Ratio-3.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.25 million
Price / Sales5.55
Cash Flow$0.0748 per share
Price / Cash46.27
Book Value$0.88 per share
Price / Book3.93
Profitability
EPS (Most Recent Fiscal Year)$0.07
Net Income$2.67 million
Net Margins-1,651.87%
Return on Equity-60.75%
Return on Assets-54.49%
Miscellaneous
Employees25
Outstanding Shares37,320,000
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma (NASDAQ:MEIP) announced its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.08. The firm earned $0.43 million during the quarter, compared to the consensus estimate of $0.40 million. MEI Pharma had a negative net margin of 1,651.87% and a negative return on equity of 60.75%. View MEI Pharma's Earnings History.
What price target have analysts set for MEIP?
3 analysts have issued 1 year price targets for MEI Pharma's shares. Their predictions range from $6.50 to $7.00. On average, they expect MEI Pharma's share price to reach $6.8333 in the next year. View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (4/12/2018)
- 2. Cann analysts commented, "MEI Pharma’s F2Q loss per share of $0.16 was higher than our estimated $0.09, due to operating expenses of $6.5 million, or 50.2% higher than our estimated $4.3 million. The higher than estimated expenses stemmed primarily from higher R&D expenses and costs associated with collaboration revenues. Higher R&D expenses are attributed to voruciclib expenses and increased R&D for ME-401. Our outlook for FY2019-23 revenue remains basically unchanged. Our FY2018 loss per share foreacast is being increased by 12% to account for higher anticipated R&D expense and costs associated with collaboration revenue." (2/8/2018)
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Insys Therapeutics (INSY), Achillion Pharmaceuticals (ACHN), Evelo Biosciences (EVLO), Isotechnika Pharma (AUPH), Zealand Pharma (ZEAL), Cytokinetics (CYTK), ObsEva (OBSV), Depomed (DEPO), Concert Pharmaceuticals (CNCE), Dermira (DERM), Innate Pharma (IPHYF), Mersana Therapeutics (MRSN), Zymeworks (ZYME), Sinovac Biotech (SVA) and GTX (GTXI).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold Ph.D., Pres, CEO & Director (Age 64)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 57)
- Mr. David M. Urso Esq., J.D., Sr. VP of Corp. Devel. and Gen. Counsel (Age 54)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 64)
- David A. Walsey, VP of IR & Corp. Communications
Has MEI Pharma been receiving favorable news coverage?
News stories about MEIP stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEI Pharma earned a news sentiment score of 0.18 on Accern's scale. They also gave news headlines about the company an impact score of 45.27 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are MEI Pharma's major shareholders?
MEI Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sio Capital Management LLC (2.50%), Russell Investments Group Ltd. (0.33%) and Algert Global LLC (0.27%). View Institutional Ownership Trends for MEI Pharma.
Which institutional investors are selling MEI Pharma stock?
Which institutional investors are buying MEI Pharma stock?
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $3.46.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $129.14 million and generates $23.25 million in revenue each year. The company earns $2.67 million in net income (profit) each year or $0.07 on an earnings per share basis. MEI Pharma employs 25 workers across the globe.
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (MEIP)
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
MEI Pharma (NASDAQ:MEIP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MEI Pharma (NASDAQ MEIP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.25%
Institutional Ownership Percentage: 22.95%
MEI Pharma (NASDAQ MEIP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/27/2017 | Charles V Baltic III | Director | Buy | 11,000 | $2.25 | $24,750.00 | 13,250 |  |
| 11/9/2015 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 390,572 | $1.84 | $718,652.48 | | |
| 1/21/2015 | Charles V Baltic III | Director | Buy | 5,000 | $3.81 | $19,050.00 | | |
| 12/9/2014 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 79,085 | $6.01 | $475,300.85 | | |
| 12/8/2014 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 9,004 | $6.05 | $54,474.20 | | |
| 6/30/2014 | Charles V Baltic III | Director | Buy | 2,000 | $6.56 | $13,120.00 | | |
| 10/29/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 299,609 | $8.21 | $2,459,789.89 | | |
| 10/2/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 581,646 | $10.16 | $5,909,523.36 | | |
| 8/16/2013 | Charles V Baltic III | Director | Buy | 2,600 | $6.82 | $17,732.00 | | |
| 6/28/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 7,337 | $7.58 | $55,614.46 | | |
| 6/11/2013 | Vivo Ventures V, Llc | Major Shareholder | Sell | 13,727 | $7.80 | $107,070.60 | | |
| 5/16/2013 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 17,428 | $9.07 | $158,071.96 | | |
| 5/8/2013 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 200,000 | $8.58 | $1,716,000.00 | | |
| 1/25/2013 | Charles V Baltic III | Director | Buy | 10,200 | $6.04 | $61,608.00 | | |
| 12/21/2012 | Charles V Baltic III | Director | Buy | 3,500 | $7.18 | $25,130.00 | | |
(Data available from 1/1/2013 forward)
MEI Pharma (NASDAQ MEIP) News Headlines
| Source: |
|
MEI Pharma (NASDAQ:MEIP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MEI Pharma (NASDAQ:MEIP) Income Statement, Balance Sheet and Cash Flow Statement
MEI Pharma (NASDAQ MEIP) Stock Chart for Sunday, May, 20, 2018
Loading chart…
